Russia's Sputnik V COVID-19 Vaccine Shows 95% Efficacy
As the race for a people's vaccine against COVID-19 picks up speed, more and more developers are announcing their efficacy results.
According to the joint statement made by Russia's health ministry, Gamaleya Scientific Research Institute, and the Russian Direct Investment Fund (RDIF), the calculations were based on preliminary data, collected 42 days after the volunteers took the first dose.
The number of cases used to make the calculation wasn't disclosed.
The vaccine had previously been reported to show 91.4% efficacy 28 days after the first dose was given to trial participants.
People who recently submitted requests will get the first batches of Sputnik V in March 2021
Russia has also stated that Sputnik V will cost less than Pfizer and Moderna's vaccine candidates, which have both shown impressive results in vaccine trials, per Frace 24.
Most recently, a statement on the official Sputnik V Twitter account announced that "The cost of one dose of the #SputnikV vaccine for the external market will be less than $10 (two doses per person is necessary) – two or more times cheaper than mRNA vaccines with similar efficacy levels (based on announced mRNA vaccines pricing & interim Phase III results)."
The vaccine will be free of charge for Russian citizens.
It is reported that RDIF will continue expanding its current agreements with international manufacturing partners to deliver the vaccine for more than 500 million people in 2020.
The Sputnik V vaccine was registered by the Ministry of Health of Russia and had become the world's first registered vaccine against COVID-19 on August 11.